Posted by: ctraderd | July 2, 2012

Biomimetic Therapeutics: A Deeper Look

Introduction:

Biomimetic Therapeutics (BMTI) is a company that develops and commercializes products that are made for the healing of musculoskeletal diseases and injuries. These products also include therapies for sports medication and orthopedic applications as well.

Stock Information:

Biomimetic Therapeutics (BMTI) has a market cap of $74.17 million and is trading 11% below its 200 day EMA (Exponential Moving Average), but 9% above its 50 day EMA.  The 50 day EMA is slowly rising, while the 200 day EMA is slowly falling. From this pattern, the EMA’s look like they are going to cross, which could be a potential buy-signal if that occurs.

As of March 31, 2012,  Biomimetic Therapeutics held $54.5 million in assets, $20.4 million of that in cash, and $34.1 million in short-term investments. BMTI is currently priced at $2.88 per share.

BMTI 

Current Developments and Products:

Currently, Biomimetic has released a bone graft called Augment in Canada, Australia, and New Zealand. Augment is currently undergoing clinical trials by the FDA in America. The bone graft was approved in Canada in November of 2009 and was approved in Australia and New Zealand in October of 2011 for use in foot and ankle indications. 

Overview of Augment: 

Augment Bone Graft is being developed as the first engineered alternative to autograft in orthopedic surgery (free of human and animal product). In clinical studies, Augment has been evaluated as a healing adjunct to fusion in foot and ankle surgeries and distal radius fractures.

The product is supplied in two primary sterile components:

  • Medical grade β-TCP granules (1000-2000 µm) granules
  • rhPDGF-BB solution (0.3 mg/mL)

At the point of use, the two components are combined, mixed and subsequently applied to the surgical site. Following mixing, the final consistency is similar to ‘wet sand’. The β-TCP component of Augment Bone Graft provides a porous, osteoconductive scaffold to support cell attachment and spreading. Augment Bone Graft is designed for use in open orthopedic surgical procedures.

Source: http://www.biomimetics.com/AugmentOverview.htm

Augmatrix Biocomposite Bone Graft is another product from Biomimetic that has been commercially released in America, but not in any other countries.

Overview of Augmatrix:

Augmatrix Biocomposite Bone Graft is a sterile, non-pyrogenic material intended for use in combination with autologous bone marrow for bone void filling of the pelvis and extremities.

The product material is a composition of:

  • Synthetic carbonated apatite (55% w/w)
  • Bovine Type I collagen (45% w/w)

Carbonated apatite is a form of calcium phosphate that closely resembles the mineral phase of natural human bone. The granules are interspersed within the collagen, thereby providing an enhanced osteoconductive scaffold to support bone remodeling. The scaffold is highly porous (80%) to allow for absorption of bone marrow aspirate (BMA) and contains ample surface area cell attachment.

The Augmatrix Biocomposite Bone Graft product family is available in a variety of configurations:

  • 2 cc Pad (2 x 2 x 0.5 cm)
  • 5 cc Strip (2 x 5 x 0.5 cm)
  • 10 cc Block (2 x 6.25 x 0.8 cm)
  • 15 mm Plug (6 and 9 mm diameter)
  • Paste (2, 5, and 10 cc volume)

A sterile, single-use 11 gauge needle (4”) is also available to assist with bone marrow aspiration. Upon saturation with BMA, Augmatrix Biocomposite Bone Graft may be manipulated as desired. This flexible structure allows the grafts to be shaped based on patient anatomy and surgical environment.

  • Pads, strips, blocks, & plugs may be compressed, folded, trimmed, or layered
  • Hydrated paste may be molded

Source: http://www.biomimetics.com/AugmatrixOverview.htm

Conclusion:

Overall, BMTI is a very volatile stock with great bone grafts released in the United States and in Canada, New Zealand and Australia. Biomimetic also has another bone graft under clinical trial by the FDA. We shall see what they release next!  

-CTraderD

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Categories

%d bloggers like this: